NCT01265836

Brief Summary

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,064

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2011

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 14, 2010

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 23, 2010

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
Last Updated

April 12, 2011

Status Verified

April 1, 2011

Enrollment Period

2 years

First QC Date

December 14, 2010

Last Update Submit

April 11, 2011

Conditions

Dyslipidemia

Keywords

Dyslipidemia Treatment and Cardiovascular Outcomes

Outcome Measures

Primary Outcomes (2)

  • The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.

    1 year

  • The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.

    1 year

Secondary Outcomes (6)

  • The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets

    1 year

  • The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1

    1 year

  • The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year

    1 year

  • The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets

    1 year

  • The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1

    1 year

  • +1 more secondary outcomes

Study Arms (1)

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Provision of subject informed consent 2. Female or male aged = 18 years 3. Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention. 4. Receiving lipid-lowering drug treatment for at least 15 days.

You may qualify if:

  • Provision of subject informed consent, Female or male aged = 18 years
  • Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

You may not qualify if:

  • Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study
  • Participation in a clinical study during the last 90 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Dyslipidemias

Condition Hierarchy (Ancestors)

Lipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Apichard Sukonthasarn, Prof.M.D.

    Maharaj Nakorn Chiangmai Hospital Cardiovascular division, Department of Internal Medicine, Faculty of Medicine, Chiangmai University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 14, 2010

First Posted

December 23, 2010

Study Start

March 1, 2011

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

April 12, 2011

Record last verified: 2011-04